Severe respiratory Diseases

Severe Respiratory Diseases

Zambon is continually searching for solutions, which will make patients’ lives better for those affected by severe respiratory diseases such as CF, BOS and NCFB.

Cystic Fibrosis

Around 100,000 people worldwide suffer from Cystic Fibrosis, the most common severe genetic disease. This multi-organ disease mainly affects the lungs, which are hit by chronic infections and inflammations that cause their progressive deterioration. 

*Sources: ECFS Patient Registry, Report 2015

200

New cases of Cystic Fibrosis every year in Italy

Source: ECFS Patient Registry, Report 2015
48%

Cases of Cystic Fibrosis affecting children in Europe

Source: ECFS Patient Registry, Report 2015

We want to develop treatments that play a key role in treating Cystic Fibrosis, as well as in managing severe respiratory diseases

Malattie respiratorie severe

Bronchiolitis Obliterans Syndrome (BOS)

BOS is a rapidly progressive disease that usually leads to respiratory failure and death within one to two years after diagnosis. BOS is caused by an inflammatory process triggered by the immune system that irreversibly destroys the airways of the lungs. BOS is most commonly seen in patients following lung transplantation and allogeneic hematopoietic stem cell transplant, though it is also associated with autoimmune disease and exposure to environmental contaminants.

75% of patients

develop BOS by 10 years post lung transplantation

13%

rate of 5 years BOS patients' survival

Zambon is supporting a full clinical development plan worldwide

Lung transplant survival is limited and has failed to improve substantially during the past two decades. Bronchiolitis obliterans is a leading cause of death. Inhalation of cyclosporine provides high bronchiolar concentrations and may arrest BOS progression. Zambon is supporting a full clinical development plan worldwide to unveil the clinical benefit of using liposomal cyclosporine inhaled formulation in patients after lung and after hematopoietic stem cell transplantation.

PIPELINE - Respiratory Tract

Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Preclinical
Anti Mycobacterial
Preclinical
New Antifungal
Preclinical
New Peptide
Preclinical
Antioxidant
Phase 2
CF
Phase 3
NCFBE-1
Phase 3
NCFBE-2
Phase 3
BOS

OUR DIRECT PRESENCE

contact
PARTNERNING OPPORTUNITIES
Business Development Department
+39 02 66524455